线粒体代谢调控与药物耐药性

Metabolic Regulation in Mitochondria and Drug Resistance.

机构信息

School of Pharmaceutical Science and Technology, Dalian University of Technology, Dalian, China.

Agi Hirshberg UCLA Center for Pancreas Diseases, University of California, Los Angeles, CA, USA.

出版信息

Adv Exp Med Biol. 2017;1038:149-171. doi: 10.1007/978-981-10-6674-0_11.

DOI:10.1007/978-981-10-6674-0_11

PMID:29178075

Abstract

Mitochondria are generally considered as a powerhouse in a cell where the majority of the cellular ATP and metabolite productions occur. Metabolic rewiring and reprogramming may be initiated and regulated by mitochondrial enzymes. The hypothesis that cellular metabolic rewiring and reprogramming processes may occur as cellular microenvironment is disturbed, resulting in alteration of cell phenotype, such as cancer cells resistant to therapeutics seems to be now acceptable. Cancer metabolic reprogramming regulated by mitochondrial enzymes is now one of the hallmarks of cancer. This chapter provides an overview of cancer metabolism and summarizes progress made in mitochondria-mediated metabolic regulation in cancer drug resistance.

摘要

线粒体通常被认为是细胞的“动力工厂”，大部分的细胞三磷酸腺苷（ATP）和代谢产物的生成都发生在这里。代谢重编程和代谢重排可能由线粒体酶启动和调节。目前，细胞代谢重编程和代谢重排过程可能是由于细胞微环境受到干扰而发生的，这导致了细胞表型的改变，例如对治疗药物产生耐药性的癌细胞，这一假说似乎已被人们所接受。受线粒体酶调控的肿瘤代谢重编程是肿瘤的特征之一。本章概述了癌症代谢，并总结了线粒体介导的代谢调控在癌症耐药性中的研究进展。